Skip to main content
. Author manuscript; available in PMC: 2022 Sep 3.
Published in final edited form as: Biochem Pharmacol. 2020 Dec 14;184:114368. doi: 10.1016/j.bcp.2020.114368

Fig. 5.

Fig. 5.

mRNA induction of CYP3A4 and CYP2B6 in HepaRG-PXR-KO cells. HepaRG and HepaRG-PXR-KO cells were treated with potential PXR agonists, CITCO (1 μM), RIF (10 μM), or the vehicle control (0.1% DMSO) as described in materials and methods. Real-time PCR was used to analyze the mRNA expression of CYP3A4 (a) and CYP2B6 (b). Each bar represents the mean ± SD in triplicate. Statistical analysis was completed between each treatment in HepaRG and HepaRG-PXR-KO cells; *, p < .05; **, p < .01; ***, p < .001.